"As US funding falters, mRNA cancer vaccine pioneers face new hurdles" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

If you think last week's decision by the federal government to halt $500 million in funding for vaccine development projects that use mRNA technology will only affect COVID vaccines, think again.

Academic researchers are worried that the government’s plans to stop investing in the development of messenger RNA vaccines, a technology university scientists first used to help develop the COVID-19 ...